HOUSE_OVERSIGHT_024103.jpg
987 KB
Extraction Summary
0
People
19
Organizations
0
Locations
0
Events
0
Relationships
2
Quotes
Document Information
Type:
Financial portfolio report / house oversight committee evidence
File Size:
987 KB
Summary
This document is a financial appendix page (marked CONFIDENTIAL) bearing a House Oversight Bates stamp (HOUSE_OVERSIGHT_024103). It details the investment performance of 'Sprout Capital VIII, L.P. (Healthcare Technology Portfolio)' as of March 31, 2014. It lists specific investments in healthcare and technology companies (such as Charles River Laboratories and eHealth, Inc.), showing the vintage year (ranging from 1998-2000), total cost, realized value, and internal rate of return (IRR) for each.
Organizations (19)
Full Extracted Text
Complete text extracted from the document (1,856 characters)
Sprout Capital VIII, L.P. (Healthcare Technology Portfolio)
$ amounts in millions, as of March 31, 2014
Please refer to Endnotes I,J,K,L,M and N in this Appendix.
$ amounts in millions, as of March 31, 2014
Please refer to Endnotes I,J,K,L,M and N in this Appendix.
Gross Multiple (Realized Portion) Gross Multiple (Total) Gross IRR
Company Sector Vintage Year Total Cost Realized Value Unrealized Value Total Value
Company Sector Vintage Year Total Cost Realized Value Unrealized Value Total Value
All Investments
Allos Therapeutics, Inc. Therapeutics 1998 $ 3.5 $ 9.8 $ - $ 9.8 2.83 2.83 47.6%
AviaHealth, Inc. (fka GoToMyDoc) Convergence 2000 $ 2.0 $ 0.0 $ - $ 0.0 0.02 0.02 -92.8%
Cephalon, Inc. Therapeutics 1999 $ 5.1 $ 25.6 $ - $ 25.6 5.01 5.01 293.2%
Charles River Laboratories Diagnostics & Infrastructure 1999 $ 4.3 $ 22.7 $ - $ 22.7 5.23 5.23 121.6%
Deltagen, Inc. Therapeutics 1998 $ 19.9 $ 4.1 $ - $ 4.1 0.20 0.20 -30.3%
eHealth, Inc. Convergence 1999 $ 11.3 $ 20.3 $ - $ 20.3 1.80 1.80 7.7%
Gantech International, Inc. Therapeutics 1999 $ 2.8 $ - $ - $ - - - NM
Keravision Inc. Healthcare Devices 1998 $ 10.2 $ - $ - $ - - - NM
Microban International, Ltd. Diagnostics & Infrastructure 1999 $ 14.8 $ 39.7 $ - $ 39.7 2.68 2.68 14.5%
Nuvelo, Inc. (fka Variagenics, Inc.) Therapeutics 1999 $ 11.8 $ 24.8 $ - $ 24.8 2.10 2.10 13.9%
NxStage Medical, Inc. Healthcare Devices 1999 $ 17.8 $ 50.3 $ - $ 50.3 2.83 2.83 14.2%
Phase Forward Incorporated Convergence 1998 $ 9.0 $ 38.6 $ - $ 38.6 4.31 4.31 22.4%
SGX, Inc. Therapeutics 2000 $ 15.0 $ 1.6 $ - $ 1.6 0.11 0.11 -35.3%
Skila, Inc. Convergence 1998 $ 9.0 $ 0.0 $ - $ 0.0 0.00 0.00 NM
Spotfire, Inc. Convergence 1999 $ 9.9 $ 24.8 $ - $ 24.8 2.50 2.50 12.7%
VascA, Inc. Healthcare Devices 1999 $ 7.3 $ 0.1 $ - $ 0.1 0.02 0.02 NM
VNUS Medical Technologies, Inc. Healthcare Devices 1999 $ 3.8 $ 11.1 $ - $ 11.1 2.90 2.90 12.7%
Allos Therapeutics, Inc. Therapeutics 1998 $ 3.5 $ 9.8 $ - $ 9.8 2.83 2.83 47.6%
AviaHealth, Inc. (fka GoToMyDoc) Convergence 2000 $ 2.0 $ 0.0 $ - $ 0.0 0.02 0.02 -92.8%
Cephalon, Inc. Therapeutics 1999 $ 5.1 $ 25.6 $ - $ 25.6 5.01 5.01 293.2%
Charles River Laboratories Diagnostics & Infrastructure 1999 $ 4.3 $ 22.7 $ - $ 22.7 5.23 5.23 121.6%
Deltagen, Inc. Therapeutics 1998 $ 19.9 $ 4.1 $ - $ 4.1 0.20 0.20 -30.3%
eHealth, Inc. Convergence 1999 $ 11.3 $ 20.3 $ - $ 20.3 1.80 1.80 7.7%
Gantech International, Inc. Therapeutics 1999 $ 2.8 $ - $ - $ - - - NM
Keravision Inc. Healthcare Devices 1998 $ 10.2 $ - $ - $ - - - NM
Microban International, Ltd. Diagnostics & Infrastructure 1999 $ 14.8 $ 39.7 $ - $ 39.7 2.68 2.68 14.5%
Nuvelo, Inc. (fka Variagenics, Inc.) Therapeutics 1999 $ 11.8 $ 24.8 $ - $ 24.8 2.10 2.10 13.9%
NxStage Medical, Inc. Healthcare Devices 1999 $ 17.8 $ 50.3 $ - $ 50.3 2.83 2.83 14.2%
Phase Forward Incorporated Convergence 1998 $ 9.0 $ 38.6 $ - $ 38.6 4.31 4.31 22.4%
SGX, Inc. Therapeutics 2000 $ 15.0 $ 1.6 $ - $ 1.6 0.11 0.11 -35.3%
Skila, Inc. Convergence 1998 $ 9.0 $ 0.0 $ - $ 0.0 0.00 0.00 NM
Spotfire, Inc. Convergence 1999 $ 9.9 $ 24.8 $ - $ 24.8 2.50 2.50 12.7%
VascA, Inc. Healthcare Devices 1999 $ 7.3 $ 0.1 $ - $ 0.1 0.02 0.02 NM
VNUS Medical Technologies, Inc. Healthcare Devices 1999 $ 3.8 $ 11.1 $ - $ 11.1 2.90 2.90 12.7%
Total Sprout Capital VIII, L.P. (HCT) Investments $ 157.5 $ 273.7 $ - $ 273.7 1.74 1.74 10.1%
92 CONTROL NUMBER 257 - CONFIDENTIAL
HOUSE_OVERSIGHT_024103
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document